Patents by Inventor Jorg Frei
Jorg Frei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20060217388Abstract: The invention relates to the treatment of leukemias with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, the substituents being defined in the specification; as well as to new phthalazine derivatives; processes for the preparation thereof; the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularization, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.Type: ApplicationFiled: May 26, 2006Publication date: September 28, 2006Inventors: Guido Bold, Janet King, Jorg Frei, Richard Heng, Paul Manley, Bernhard Wietfeld, Jeanette Wood
-
Patent number: 6911440Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, the substituents being defined in the specification; as well as to new phthalazine derivatives; processes for the preparation thereof, the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularization, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.Type: GrantFiled: November 26, 2003Date of Patent: June 28, 2005Assignee: Novartis AGInventors: Guido Bold, Janet Dawson King, Jörg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood
-
Publication number: 20040142934Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, 1Type: ApplicationFiled: November 26, 2003Publication date: July 22, 2004Inventors: Guido Bold, Janet Dawson King, Jorg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood
-
Patent number: 6710047Abstract: The invention relates to compounds of formula I, wherein r is 0 to 2, n is 0 to 2; m is 0 to 4; R1 and R2 (i) are in each case a lower alkyl, or (ii) together form a bridge in subformula I* or (iii) together form a bridge in subformula I** wherein one or two of the ring members T1, T2, T3, and T4 are nitrogen, and the remainder are in each case CH; A, B, D, and E are N or CH, wherein not more than 2 of these radicals are N; G is lower alkylene, acyloxy- or hydroxy-lower alkylene, —CH2—O—, —CH2—S—, —CH2—NH—, oxa, thia, or imino; Q is methyl; R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl, pyridyl, or (un)substituted cycloalkyl; and Z is mono- or disubstited amino, halogen, alkyl, substituted alkyl, hydroxy, etheritied or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, pType: GrantFiled: January 7, 2003Date of Patent: March 23, 2004Assignee: Novartis AGInventors: Guido Bold, Jörg Frei, Peter Traxler, Karl-Heinz Altmann, Helmut Mett, David Raymond Stover, Jeanette Marjorie Wood
-
Patent number: 6686347Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, the substituents being defined in the specification; as well as to new phthalazine derivatives; processes for the preparation thereof; the application thereof in a process for the treatment of the human or animal body; the use thereof for the treatment of a disease, especially a disease caused by ocular neovascularization, such as age-related macula degeneration or diabetic retinopathy, or other diseases that respond to the inhibition of tyrosine kinases, such as a proliferative disease; a method for the treatment of such disease in mammals; and the use of such a compound for the manufacture of a pharmaceutical preparation for the treatment especially of a disease as mentioned above.Type: GrantFiled: September 26, 2001Date of Patent: February 3, 2004Assignee: Novartis AGInventors: Guido Bold, Janet Dawson King, Jörg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood
-
Publication number: 20030191129Abstract: The invention relates to compounds of formula I, 1Type: ApplicationFiled: January 7, 2003Publication date: October 9, 2003Inventors: Guido Bold, Jorg Frei, Peter Traxler, Karl-Heinz Altmann, Helmut Mett, David Raymond Stover, Jeanette Marjorie Wood
-
Patent number: 6514974Abstract: The invention relates to compounds of formula I, wherein r is 0 to 2, n is 0 to 2; m is 0 to 4; R1 and R2 (i) are in each case a lower alkyl, or (ii) together form a bridge in subformula I* or (iii) together form a bridge in subformula I** wherein one or two of the ring members T1, T2, T3, and T4 are nitrogen, and the remainder are in each case CH; A, B, D, and E are N or CH, wherein not more than 2 of these radicals are N; G is lower alkylene, acyloxy- or hydroxy-lower alkylene, —CH2—O—, —CH2—S—, —CH2—NH—, oxa, thia, or imino; Q is methyl; R is H or lower alkyl; X is imino, oxa, or thia; Y is aryl, pyridyl, or (un)substituted cycloalkyl; and Z is mono- or disubstited amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, pType: GrantFiled: May 17, 2001Date of Patent: February 4, 2003Assignee: Novartis AGInventors: Guido Bold, Jörg Frei, Peter Traxler, Karl-Heinz Altmann, Helmut Mett, David Raymond Stover, Jeanette Marjorie Wood
-
Publication number: 20030013718Abstract: The invention relates to the treatment of an inflammatory disease, especially an inflammatory rheumatoid or rheumatic disease, and/or pain with an inhibitor of the activity of VEGF receptor tyrosine kinase of the formula I, 1Type: ApplicationFiled: September 26, 2001Publication date: January 16, 2003Inventors: Guido Bold, Janet Dawson King, Jorg Frei, Richard Heng, Paul William Manley, Bernhard Wietfeld, Jeanette Marjorie Wood
-
Publication number: 20020091261Abstract: The invention relates to compounds of formula I, 1Type: ApplicationFiled: May 17, 2001Publication date: July 11, 2002Inventors: Guido Bold, Jorg Frei, Peter Traxler, Karl-Heinz Altmann, Helmut Mett, David Raymond Stover, Jeanette Marjorie Wood
-
Patent number: 6258812Abstract: The invention relates to compounds of formula I, wherein r is 0 to 2, n is 0 to 2; m is 0 to 4; R1 and R2 (i) are in each case a lower alkyl, or (ii) together form a bridge in subformula I* (I*) or (iii) together form a bridge in subformula I** (I**), wherein one or two of the ring members T1, T2, T3, and T4 are nitrogen, and the remainder are in each case CH; A, B, D, and E are N or CH, wherein not more than 2 of these radicals are N; G is lower alkylene, acyloxy- or hydroxy-lower alkylene, —CH2—O—, —CH2—S—, —CH2—NH—, oxa, thia, or imino; Q is methyl; c is H or lower alkyl; X is imino, oxa, or thia; Y is aryl, pyridyl, or (un)substituted cycloalkyl; and Z is mono- or disubstited amino, halogen, alkyl, substituted alkyl, hydroxy, etherified or esterified hydroxy, nitro, cyano, carboxy, esterified carboxy, alkanoyl, carbamoyl, N-mono- or N,N-disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, pType: GrantFiled: October 20, 1999Date of Patent: July 10, 2001Assignee: Novartis AGInventors: Guido Bold, Jörg Frei, Peter Traxler, Karl-Heinz Altmann, Helmut Mett, David Raymond Stover, Jeanette Marjorie Wood
-
Patent number: 6251911Abstract: 4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula I wherein the substituents are as defined in claim 1, are described. These compounds inhibit the tyrosine kinase activity of the receptor for epidermal growth factor (EGF) and c-erbB2 kinase and can be used as anti-tumor agents.Type: GrantFiled: April 1, 1999Date of Patent: June 26, 2001Assignee: Novartis AGInventors: Guido Bold, Jörg Frei, Marc Lang, Peter Traxler
-
Patent number: 6180636Abstract: There are described 7H-pyrrolo[2,3-d]pyrimidine derivatives of the formula I in which the substituents are as defined in claim 1. These compounds inhibit the tyrosine kinase activity of the receptor for the epidermal growth factor (EGF) and c-erbB2 kinase and can be used as anti-tumor agents.Type: GrantFiled: February 19, 1999Date of Patent: January 30, 2001Assignee: Novartis AGInventors: Peter Traxler, Guido Bold, Marc Lang, Jörg Frei
-
Patent number: 6140332Abstract: Described are 7H-pyrrolo[2,3-d]pyrimidine derivatives of formula I ##STR1## wherein the symbols are as defined in claim 1. Those compounds inhibit tyrosine protein kinase and can be used in the treatment of hyperproliferative diseases, for example tumour diseases.Type: GrantFiled: January 26, 1998Date of Patent: October 31, 2000Assignee: Novartis AGInventors: Peter Traxler, Guido Bold, Wolfgang Karl-Diether Brill, Jorg Frei
-
Patent number: 6140317Abstract: There are described compounds of formula I ##STR1## wherein R.sub.1 and R.sub.2 are as defined in the description, Q is heterocyclyl boned via a ring nitrogen atom and having the formula IA ##STR2## wherein R.sub.3 and R.sub.4 and m and n are as defined in the description, the ring marked A is a heterocyclyl having 5 to 9 ring atoms and having at least one saturated bond, it being possible for a further ring hetero atom selected from O and S to be present in addition to the bonding nitrogen atom, the ring system marked B is a free or benzo-, thieno-, furo-, pyrrolo- or dihydropyrrolo-fused carbocyclic ring having from 5 to 9 carbon atoms that is fused to the ring A and may be unsaturated, partially saturated or fully saturated, and the bond marked by a parallel dotted line between the ring systems marked A and B is either a single bond or a double bond, and a salt thereof where at least one salt-forming group is present.Type: GrantFiled: July 22, 1998Date of Patent: October 31, 2000Assignee: Novartis AGInventors: Peter Traxler, Jorg Frei, Guido Bold
-
Patent number: 5981533Abstract: 4-Amino-1H-pyrazolo[3,4-d]pyrimidine derivatives of formula I ##STR1## wherein the symbols are as defined in claim 1, and intermediates for their manufacture are described.The compounds of formula I inhibit especially the tyrosine kinase activity of the receptor for epidermal growth factor and can be used, for example, in the case of epidermal hyperproliferation (psoriasis) and as anti-tumor agents.Type: GrantFiled: October 3, 1997Date of Patent: November 9, 1999Assignee: Novartis AGInventors: Peter Traxler, Pascal Furet, Guido Bold, Jorg Frei, Marc Lang
-
Patent number: 5840911Abstract: Described are compounds of formula I ##STR1## wherein R.sub.1 is hydrogen or hydroxy;R.sub.2, R.sub.2 ' and R.sub.2 " are each independently of the others hydrogen or a substituent other than hydrogen;eitherR.sub.3 is hydrogen or a substituent other than hydrogen andR.sub.4 is hydrogen or lower alkyl,orR.sub.3 and R.sub.4 together form a divalent radical of the formula --(CH.sub.2).sub.n -- wherein n is 2 or 3;R.sub.5 and R.sub.6 are each independently of the other hydrogen, alkyl or aryl; andeither R.sub.7 and R.sub.8 are each hydrogen, or R.sub.7 and R.sub.8 together form a bond; tautomers thereof, provided that at least one tautomerisable group is present; and salts thereof.The compounds inhibit the enzyme S-adenosylmethionine decarboxylase and are suitable, for example, for the treatment of tumours and protozoal infections.Type: GrantFiled: July 23, 1997Date of Patent: November 24, 1998Assignee: Novartis AGInventors: Jorg Frei, Jaroslav Stanek
-
Patent number: 5834486Abstract: The invention relates to compounds of formula (I) ##STR1## wherein either R.sub.1 is hydrogen andR.sub.2 is lower alkyl lower alkenyl or lower alkynyl,m is 3 or 4 andn is 2 or 3;orR.sub.1 and R.sub.2 together are tetrainethylene,m is 3 or 4 andn is 2;or salts thereof.The compounds of formula (I) influence polyamine biosynthesis and have antiproliferative activity as well as an action against protozoans.Type: GrantFiled: September 15, 1997Date of Patent: November 10, 1998Assignee: Novartis AGInventors: Jorg Frei, Jaroslav Stanek
-
Patent number: 5639911Abstract: Compounds of formula I ##STR1## wherein A, X, Z and R.sub.1 -R.sub.5 are as defined in the description, and their salts have valuable pharmaceutical properties and are effective especially against tumours. They are prepared in a manner known per se.Type: GrantFiled: June 7, 1995Date of Patent: June 17, 1997Assignee: Ciba-Geigy CorporationInventors: Jaroslav Stanek, Jorg Frei, Giorgio Caravatti
-
Patent number: 5627215Abstract: The invention relates to compounds of formula (I), R.sub.1 and R.sub.2, each independently of the other, are selected from lower alkyl that is unsubstituted or substituted by one or more fluorine atoms which are not linked to the carbon atom of R.sub.1 or R.sub.2 bonding the nitrogen; from lower alkenyl wherein the double bond does not originate from the carbon atom that is bonded to a nitrogen bonding R.sub.1 or R.sub.2 ; from lower alkynyl wherein the triple bond does not originate from the carbon atom that is bonded to a nitrogen bonding R.sub.1 or R.sub.2 ; from cycloalkyl; and from cycloalkyl-lower alkyl; with the proviso that not more than one of the two radicals R.sub.1 and R.sub.2 is methyl; or salts thereof. The mentioned compounds are pharmacologically active against disorders that are responsive to a recuction in intracellular polyamines, such as tumours or protozoal diseases.Type: GrantFiled: August 18, 1995Date of Patent: May 6, 1997Assignee: Ciba-Geigy CorporationInventors: Jorg Frei, Jaroslav Stanek
-
Patent number: 5516806Abstract: Compounds of formula (I): H.sub.2 N--(CH.sub.2).sub.n --A--(CH.sub.2).sub.m --O--NH.sub.2 and salts thereof are described in which the radical A is C.sub.3 -C.sub.6 cycloalkylene; n is 0 or 1 and, independently thereof, m is 0 or 1; with the provisos that a) the distance between the aminooxy radical H.sub.2 N--O-- and the amino group --NH.sub.2 is at least 3 and not more than 4 carbon atoms and that b) the two radicals H.sub.2 N--(CH.sub.2).sub.n -- and --(CH.sub.2).sub.m --O--NH.sub.2 are not bonded to the same ring carbon of A. The compounds of formula (I) and their salts are ornithine decarboxylase inhibitors.Type: GrantFiled: December 12, 1994Date of Patent: May 14, 1996Assignee: Ciba-Geigy CorporationInventors: Jorg Frei, Jaroslav Stanek